Home/Pipeline/ViraxImmune™ PAIS Assay

ViraxImmune™ PAIS Assay

Post-Acute Infection Syndrome (PAIS) / Immune Dysfunction

DevelopmentActive; FDA Pre-Submission Meeting Scheduled

Key Facts

Indication
Post-Acute Infection Syndrome (PAIS) / Immune Dysfunction
Phase
Development
Status
Active; FDA Pre-Submission Meeting Scheduled
Company

About Virax Biolabs

Virax Biolabs is a public immunology diagnostics company focused on decoding the adaptive immune response to address unmet needs in chronic, post-infectious conditions such as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Its strategy is built on a dual business model: providing research-use-only (RUO) products to the scientific community while advancing its core ViraxImmune™ platform toward FDA-regulated in-vitro diagnostics (IVDs). Key recent achievements include a clinical partnership with Emory University and preparations for an FDA pre-submission meeting, positioning the company to potentially deliver the first objective blood-based diagnostic for Post-Acute Infection Syndrome (PAIS).

View full company profile